• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    5/13/24 8:06:42 AM ET
    $APDN
    $CCLD
    $DYNT
    $FTRE
    Other Consumer Services
    Consumer Discretionary
    Computer Software: Prepackaged Software
    Technology
    Get the next $APDN alert in real time by email

    Gainers

    • Tevogen Bio Holdings (NASDAQ:TVGN) stock rose 55.4% to $1.53 during Monday's pre-market session. The market value of their outstanding shares is at $251.8 million.
    • MiNK Therapeutics (NASDAQ:INKT) stock increased by 31.09% to $1.18. The company's market cap stands at $40.9 million.
    • Dynatronics (NASDAQ:DYNT) stock increased by 21.69% to $0.57. The company's market cap stands at $2.8 million. As per the press release, Q3 earnings came out 2 days ago.
    • Tarsus Pharmaceuticals (NASDAQ:TARS) shares moved upwards by 18.08% to $43.69. The market value of their outstanding shares is at $1.6 billion. As per the news, the Q1 earnings report came out 3 days ago.
    • CareCloud (NASDAQ:CCLD) shares increased by 15.07% to $1.45. The company's market cap stands at $23.3 million.
    • Fulcrum Therapeutics (NASDAQ:FULC) shares rose 13.78% to $8.5. The market value of their outstanding shares is at $528.3 million. The company's, Q1 earnings came out today.

    Losers

    • Applied DNA Sciences (NASDAQ:APDN) stock declined by 13.1% to $3.0 during Monday's pre-market session. The market value of their outstanding shares is at $2.5 million. As per the news, the Q2 earnings report came out yesterday.
    • Portage Biotech (NASDAQ:PRTG) shares declined by 12.81% to $0.22. The market value of their outstanding shares is at $4.3 million.
    • TransCode Therapeutics (NASDAQ:RNAZ) stock fell 12.06% to $1.24. The market value of their outstanding shares is at $7.5 million.
    • Fortrea Holdings (NASDAQ:FTRE) stock fell 9.09% to $30.03. The company's market cap stands at $2.6 billion. The company's, Q1 earnings came out today.
    • NovaBay Pharmaceuticals (AMEX:NBY) shares declined by 9.08% to $0.07. The company's market cap stands at $2.6 million. The company's, Q1 earnings came out 2 days ago.
    • 60 Degrees (NASDAQ:SXTP) stock decreased by 8.89% to $0.2. The market value of their outstanding shares is at $2.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APDN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APDN
    $CCLD
    $DYNT
    $FTRE

    CompanyDatePrice TargetRatingAnalyst
    Fulcrum Therapeutics Inc.
    $FULC
    1/12/2026$20.00Overweight
    Analyst
    Fortrea Holdings Inc.
    $FTRE
    1/8/2026$22.00Hold → Buy
    Truist
    Fortrea Holdings Inc.
    $FTRE
    1/6/2026$25.00In-line → Outperform
    Evercore ISI
    Fortrea Holdings Inc.
    $FTRE
    12/15/2025$15.00Underweight → Equal Weight
    Barclays
    Fortrea Holdings Inc.
    $FTRE
    12/11/2025$21.00Neutral → Buy
    Citigroup
    Tarsus Pharmaceuticals Inc.
    $TARS
    12/9/2025$100.00Overweight
    Barclays
    Fulcrum Therapeutics Inc.
    $FULC
    11/24/2025Buy
    Truist
    Tarsus Pharmaceuticals Inc.
    $TARS
    11/20/2025$100.00Outperform
    Mizuho
    More analyst ratings

    $APDN
    $CCLD
    $DYNT
    $FTRE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Dow Geoffrey S bought $7,759 worth of shares (9,670 units at $0.80), increasing direct ownership by 19% to 59,618 units (SEC Form 4)

    4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

    12/16/25 5:41:35 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Dow Geoffrey S bought $12,204 worth of shares (12,963 units at $0.94), increasing direct ownership by 35% to 49,948 units (SEC Form 4)

    4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

    12/12/25 8:39:45 AM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Russell Erin L bought $100,018 worth of shares (9,854 units at $10.15) (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    9/4/25 4:39:23 PM ET
    $FTRE
    Medical Specialities
    Health Care

    $APDN
    $CCLD
    $DYNT
    $FTRE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization

    WARREN, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent ("LoI") to evaluate a potential transaction with a distinguished global Contract Research Organization ("CRO"). If consummated, the proposed transaction could expand Tevogen's clinical development capabilities and could support the Company's evolution into a revenue-generating healthcare enterprise. Dr. Ryan Saadi, Founder and Chief Executive Officer of Tevogen, stated, "The potential acquisition of a CRO could introduce revenue-generating service capabilities while allowing us to opt

    2/27/26 2:20:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tarsus to Participate in Upcoming Investor Conferences

    IRVINE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that management plans to participate in the following upcoming investor conferences: TD Cowen 46th Annual Health Care Conference on Tuesday, March 3rd, at 11:30 a.m. PT / 2:30 p.m. ET.Barclays 28th Annual Global Healthcare Conference on Wednesday, March 11th, at 9:30 a.m. PT / 12:30 p.m. ET. Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and will be archived for a limited time. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc. applies proven science

    2/26/26 4:30:00 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus

    WARREN, N.J. and ROYAL OAK, Mich., Feb. 26, 2026 (GLOBE NEWSWIRE) --  Tevogen ("Tevogen Bio Holdings Inc.") (NASDAQ:TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent ("LoI") to evaluate a potential transaction with Sciometrix Inc. ("Sciometrix"), a privately held healthcare technology and value-based care solutions provider headquartered in Michigan and developer of the Clinicus digital care management platform, that would, if consummated, result in Tevogen holding a majority voting interest in Sciometrix. The potential transaction is being explored to augment Tevogen's existing capabilities and would result in Tevogen becoming a revenue-

    2/26/26 4:22:45 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APDN
    $CCLD
    $DYNT
    $FTRE
    SEC Filings

    View All

    SEC Form 10-K filed by Fortrea Holdings Inc.

    10-K - Fortrea Holdings Inc. (0001965040) (Filer)

    2/26/26 4:04:36 PM ET
    $FTRE
    Medical Specialities
    Health Care

    SEC Form 424B3 filed by Tevogen Bio Holdings Inc.

    424B3 - Tevogen Bio Holdings Inc. (0001860871) (Filer)

    2/26/26 9:36:37 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fortrea Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Fortrea Holdings Inc. (0001965040) (Filer)

    2/26/26 6:05:44 AM ET
    $FTRE
    Medical Specialities
    Health Care

    $APDN
    $CCLD
    $DYNT
    $FTRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Pyott David E I

    4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)

    2/20/26 4:35:48 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New insider Pyott David E I claimed ownership of 7,991 shares (SEC Form 3)

    3 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)

    2/20/26 4:35:33 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Operating Officer Morais Mark A. converted options into 2,255 shares and sold $16,365 worth of shares (1,179 units at $13.88), increasing direct ownership by 2% to 58,052 units (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    2/11/26 7:04:31 PM ET
    $FTRE
    Medical Specialities
    Health Care

    $APDN
    $CCLD
    $DYNT
    $FTRE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XDEMVY issued to TARSUS PHARMACEUTICALS, INC.

    Submission status for TARSUS PHARMACEUTICALS, INC.'s drug XDEMVY (ORIG-1) with active ingredient LOTILANER has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity

    7/25/23 4:35:13 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for issued to TARSUS PHARMACEUTICALS, INC.

    Submission status for TARSUS PHARMACEUTICALS, INC.'s drug (ORIG-1) with active ingredient has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity

    7/25/23 4:35:13 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for issued to TARSUS PHARMACEUTICALS, INC

    Submission status for TARSUS PHARMACEUTICALS, INC's drug (SUPPL-1) with active ingredient has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity

    7/25/23 4:29:16 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APDN
    $CCLD
    $DYNT
    $FTRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on Fulcrum Therapeutics with a new price target

    Analyst initiated coverage of Fulcrum Therapeutics with a rating of Overweight and set a new price target of $20.00

    1/12/26 8:13:43 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fortrea upgraded by Truist with a new price target

    Truist upgraded Fortrea from Hold to Buy and set a new price target of $22.00

    1/8/26 8:10:34 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Fortrea from In-line to Outperform and set a new price target of $25.00

    1/6/26 8:26:05 AM ET
    $FTRE
    Medical Specialities
    Health Care

    $APDN
    $CCLD
    $DYNT
    $FTRE
    Leadership Updates

    Live Leadership Updates

    View All

    Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors

    IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced the appointment of David E. I. Pyott, a distinguished leader in the global biopharmaceutical industry and former Chairman and CEO of Allergan, Inc., to its Board of Directors. "David is one of the most accomplished leaders in eye care, with a strong track record of translating innovation into global impact," said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. "His experience building some of the most successful franchises in our industry will be invaluable as we scale XDEMVY, advance our pipeline and position Tarsus for sustained growth. We are honored

    2/18/26 8:30:00 AM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CareCloud Appoints Chief Strategy Officer to Lead Enterprise AI Platform as Company Enters 2026 as Its Defining AI Year

    Strategic leadership alignment positions CareCloud to scale execution, expand margins, and accelerate AI-driven innovation across ambulatory and hospital markets SOMERSET, N.J., Dec. 29, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (NASDAQ:CCLD, CCLDO)), ("CareCloud" or the "Company") a leader in healthcare technology and AI-powered solutions, today announced leadership promotions designed to align the organization for its next phase of growth and to position 2026 as a defining year for enterprise AI innovation across the Company's platform. Effective January 1, 2026, A. Hadi Chaudhry will serve as Chief Strategy Officer, leading CareCloud's enterprise AI vision, platform innovation, and com

    12/29/25 8:00:00 AM ET
    $CCLD
    Computer Software: Prepackaged Software
    Technology

    TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

    BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

    12/22/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APDN
    $CCLD
    $DYNT
    $FTRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Applied DNA Sciences Inc.

    SC 13G - APPLIED DNA SCIENCES INC (0000744452) (Subject)

    11/14/24 5:46:25 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Tevogen Bio Holdings Inc.

    SC 13G/A - Tevogen Bio Holdings Inc. (0001860871) (Subject)

    11/14/24 5:29:01 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Tarsus Pharmaceuticals Inc.

    SC 13G - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)

    11/14/24 4:41:12 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APDN
    $CCLD
    $DYNT
    $FTRE
    Financials

    Live finance-specific insights

    View All

    Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance

    Revenue and Adjusted EBITDA results delivered in line with stated full-year targetsFull‑year cost savings exceeded previously communicated targets Highlights: Revenues of $660.5 million for the fourth quarter and $2,723.4 million for the full yearFourth-quarter book-to-bill ratio of 1.14x, resulting in 1.02x book-to-bill for the trailing 12 monthsGAAP net loss of $(32.5) million, or $(0.35) per diluted share for the fourth quarter; $(986.2) million, or $(10.81) per diluted share for the full yearAdjusted EBITDA of $54.0 million for the fourth quarter and $189.9 million for the full yearAdjusted net income of $9.2 million, or $0.09 per diluted share for the fourth quarter; $40.4 million, or

    2/26/26 6:00:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

    ― Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12), representing a rapid, robust, and clinically relevant response, with progression toward pan-cellular HbF induction as F-cells increased from 31% to 63% ― ― 7 of 12 patients (58%) achieved absolute HbF levels ≥20%; all patients achieved at least a 6.5% absolute increase in HbF ― ― Improvements in markers of hemolysis, improved erythropoiesis, and a >1 g/dL increase in total hemoglobin ― ― 7 of 12 patients (58%) reported zero VOCs during the treatment period ― ― Pociredir was generally well-tolerated, with no treatment-related serious adverse events (SAEs) ― ― Fulcrum plans to initiate a pote

    2/24/26 7:00:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements

    Generated full-year 2025 net product sales of XDEMVY® of $451.4 million, an increase of more than 150% year-over-year Providing expected XDEMVY peak sales potential of more than $2 billion Extending category-creating leadership with initiation of Phase 2 trial of TP-04 in ocular rosacea (OR) and plans to initiate a Phase 2 trial of TP-05 for Lyme disease prevention in Q2 2026 Management to host conference call today, February 23, 2026, at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced financial results for the fourth quarter and full-year ended December 31, 2025, and recent business achievements.

    2/23/26 4:05:00 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care